COMPANY PRESENTATION JEFFERIES HEALTHCARE CONFERENCE JUNE 2015

Transcription

1 COMPANY PRESENTATION JEFFERIES HEALTHCARE CONFERENCE JUNE 2015

2 FORWARD LOOKING STATEMENT This document has been prepared by Innate Pharma S.A. (the Company ) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company s actual results or financial condition to differ materially from those anticipated. Please refer to the risk factors outlined from time to time in the Company s regulatory filings or publications. This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of these data comes from external sources that are recognized in the field or from Company s estimates based on such sources. The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice. The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith. Please refer to the Document de Référence filed with the Autorité des marchés financiers ( AMF ), available on the AMF s website ( and on the Company s website ( Such documents may not be necessarily up to date. This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country. Page 2

3 INNATE PHARMA AT A GLANCE Leading scientific edge in innate immunity pharmacology Primary focus in immuno-oncology Portfolio of first-in-class checkpoint inhibitors Partnerships with leaders in IO BMS and AZN Page 3

4 PARTNERSHIP WITH ASTRAZENECA Acceleration of IPH2201 development > Phase II combination trials with MEDI4736, AZN anti-pd-l1, in solid tumors > 4 Phase II trials planned by Innate, single agent and combination > Development of associated biomarkers Global co-development and co-promotion agreement for IPH2201 > Initial payment: $250 million > Further $100 million prior to initiation of Phase III development, > Additional regulatory and sales-related milestones of up to $925 million > Double digit royalties on net sales and right for Innate Pharma to co-promote in Europe for 50% profit share in the territory Page 4

5 A LONG TERM STRATEGY IN ACTION 2015 Co-development and co-promotion of IPH Licence of lirilumab R&D collaboration Page 5

6 INNATE PHARMA PIPELINE PROGRAM TARGET INDICATIONS AND SETTING ONGOING STUDIES Lirilumab (IPH2102/BMS ) licensed to Bristol-Myers Squibb KIR2DL1,2,3 AML, single agent Solid & heme tumors Multiple combinations Randomized Phase II 5 Phase I and II trials IPH2201 co-development with AstraZeneca NKG2A Solid & heme tumors Multiple combinations Phase II IPH4102 KIR3DL2 Cutaneous T-cell lymphomas Phase I start in 2015 IPH33 TLR3 Inflammation / Autoimmunity Preclinical IPH43 MICA Cancer Preclinical Other / Discovery Undisclosed Cancer / Inflammation Preclinical Page 6

7 Agonist antibodies Checkpoint inhibitors CLINICAL PIPELINE OF IMMUNOMODULATING MABS IN CANCER TARGET PHASE I PHASE II PHASE III MARKET CTLA-4 AZN BMS PD-1 AZN BMS/ONO, Merck PD-L1 BMS Pfizer/Merck KGaA Roche, AZN KIR NKG2A IPH/BMS IPH/AZN LAG-3 BMS CD137 B7-H3 CD40 OX40 GITR CD27 Pfizer, BMS Servier/MGNX Roche AZN, Roche GITR Inc, Merck Celldex AMP: Amplimmune; CRUK: Cancer Research UK; MGNX: MacroGenix; IMP: Immutep Page 7

8 LIRILUMAB FIRST-IN-CLASS ANTI-KIR MAB

9 THERAPEUTIC POTENTIAL OF NK CELLS IN ACUTE MYELOID LEUKEMIA NK cells can protect against tumor relapse, leading to improved survival in AML patients after stem cell transplantation Effects are: NK activation NK inhibition Durable Safe Controlled by KIR Mediated by NK cells Velardi et al., Science, 2002 (not shown) Ruggeri et al, Blood, 2007 Page 9

10 LIRILUMAB FIRST-IN-CLASS NK CELL CHECKPOINT INHIBITOR Fully human antibody (IgG4) blocking NK cell inhibitory receptor KIR2DL1/2/3 Prevents interaction with HLA class 1 molecules to potentiate NK anti-tumor activity Development and commercialization rights licensed to Bristol-Myers Squibb $35 million upfront, up to $430 million in milestone payments, double-digit royalties (signed July 2011) Anti-KIR KIR HLA-C KIR HLA-C NK cell Tumor cell + + Activating receptor Activating ligand NK inhibition by KIR + Activating receptor Activating ligand Activation through KIR blockade Page 10

11 Combination CLINICAL PROGRAM WITH LIRILUMAB SETTING PATIENTS (PLANNED) INDICATION STATUS Monotherapy Randomized Phase II 150 Acute Myeloid Leukemia Maintenance setting LFS expected 2Q 2016 Nivolumab Phase I with cohort expansion 162 Selected solid tumors: MEL, NSCLC, GI, SCCHN, HCC Enrollment close to completion Nivolumab Phase I 315 (1) Relapsed/refractory Selected hematologic tumors: NHL, HL, MM or CML Started in October 2014 Elotuzumab Phase I with randomized cohort expansion 136 (2) Multiple myeloma: Relapsed/refractory MM Post autologous transplant Started in October azacytidine (Vidaza) Phase II with dose escalation 64 Acute Myeloid Leukemia Relapsed/refractory Started in April 2015 Ipilimumab Phase I with cohort expansion 125* Selected solid tumors: NSCLC, CRPC, MEL Enrollment stopped in Dec (1) Three arms (nivo, nivo + ipi, nivo + liri) / (2) Two arms (elo + liri, elo + ure); *originally planned Page 11

12 EFFIKIR PHASE II TRIAL DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED TRIAL IN AML Target enrollment completed in July 2014 (150 patients) Data on LFS expected 2Q16 One active arm stopped in March 2015 upon DSMB recommendation 1:1:1 Elderly 1 st complete remission Max 2 consolidations Not eligible for HST Minimization Center 1º vs 2 nd AML No. consolidations Cytogenetics R A N D O M I Z E Lirilumab 0.1 mg/kg q 12 weeks Intermittent full KIR occupancy Lirilumab 1.0 mg/kg q 4 weeks Continuous full KIR occupancy Placebo q 4 weeks Treatment for 2 years Primary endpoint: Leukemia-Free Survival (Independent Review Committee) N=50 per arm Maximum follow-up period: 24 months after last patient entry ClinicalTrials.gov Identifier: NCT Page 12

13 IPH2201 FIRST-IN-CLASS ANTI-NKG2A MAB

14 IPH2201 TARGETS NKG2A CHECKPOINT INHIBITORY RECEPTOR ON NK AND CD8 T CELLS NKG2A is a inhibitory receptor on tumor infiltrating CD8 T cells and NK cells Anti-NKG2A NKG2A HLA-E NK cell Tumor cell + + Activating receptor Activating ligand NKG2A HLA-E MHC Anti-NKG2A TCR T cell NK and T cell inhibition by NKG2A + Activation through NKG2A blockade Page 14

15 MANY TUMORS OVEREXPRESS NKG2A LIGAND SUGGESTING A MAJOR MECHANISM OF IMMUNE EVASION HLA-E upregulated on a wide variety of tumor types Nb of patients Source: internal data Page 15

16 Combination PHASE II PROGRAM SETTING INDICATION STATUS Monotherapy Phase Ib/II Head & Neck Started in December 2014 Monotherapy Phase II High grade ovarian cancer Start expected in 2015 Ibrutinib Phase II Chronic Lymphocytic Leukemia Start expected in 2015 Cetuximab Phase I/II Head & Neck Start expected in 2015 MEDI4736 (anti-pd-l1) Phase II Solid tumors To be started (AZN) Page 16

17 PERSPECTIVES

18 MAIN NEWS IN / EXPECTED NEWSFLOW Lirilumab EffiKIR Phase II fully enrolled Combination in solid tumors close to full enrollment New combination trials in heme malignancies IPH2201 Acquisition of full rights to IPH2201 First patient in Phase II Co-development / co-promotion agreement w. AZ Lirilumab: start of clinical trials read-out IPH2201 Phase II trials roll out IPH4102 Orphan drug designation in the European Union IPH4102: start of Phase I trial Corporate 70m raised from specialist investors $250m initial payment for AZ agreement Expanded clinical team Further pipeline growth Page 18

19 INVESTOR RELATIONS Laure-Hélène Mercier Sr Director, Investor relations Tel: +33 (0) Fax: +33 (0)